Bevacizumab biosimilar(United Biopharma)

贝伐珠单抗生物类似药（联合生物）

Report date: 2022/03/16 17:41:43

Base Information

Drug NameBevacizumab biosimilar(United Biopharma)
Drug Alias Namebevacizumab biosimilar(United Biopharma)贝伐珠单抗生物仿制药（联合生物）贝伐单抗生物仿制药（联合生物）贝伐单抗生物类似药（联合生物）贝伐人源化单抗生物仿制药（联合生物） +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungBrain Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUnited Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesUnited Biopharma Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerCarcinoma, Non-Small-Cell LungBrain Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A